GET DAILY SIGNALSInflaRx N.V. (IFRX): Analyst Average Points to $7.60 With +358% Upside
Key Takeaways
- The central price target used here is $7.60, the arithmetic mean of eight verified analyst price targets.
- At the latest close of $1.66, reaching $7.60 would require a gain of roughly 358%, a very large move.
- The individual targets span an unusually wide range, from $2.00 to $14.00, reflecting deep disagreement about the pipeline's value.
- The strongest supports are the izicopan program in AAV, a recent $150 million financing that extends the cash runway, and a series of bullish target increases in 2026.
- The biggest risks are clinical-trial uncertainty, no recurring product revenue, potential dilution, and a notable Market Perform rating with a $2 target from Leerink Partners.
- For more context on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
- Readers can also browse Trending AI Robots for AI-driven market insights across thousands of securities.
Analyst Price Targets and Consensus View
The central target reflects eight individually attributable analyst price targets, not a website's headline consensus. The arithmetic mean of these targets is approximately $7.63, rounded to $7.60. The low is Leerink Partners at $2.00 (a December 2025 downgrade to Market Perform), and the high is Guggenheim's Yatin Suneja at $14.00 (May 2026). I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent actions lean bullish. Raymond James upgraded IFRX to Strong Buy in May 2026 and raised its target from $7 to $9, citing the izicopan AAV program and a $150 million financing that extends runway into proof-of-concept development. H.C. Wainwright's Matthew Keller raised his target to $8 from $6, and Needham initiated coverage with a Buy and an $8 target in September 2026. Cantor Fitzgerald lifted its target to $6 from $4 in August, while Oppenheimer reiterated $9 and LifeSci Capital maintained $5. The wide $2–$14 spread shows analysts are valuing the same pipeline very differently.
Current Market Position and Path Toward the Target
IFRX closed at $1.66 on October 27, 2026, up 5.4% on the session, with a market capitalization near $232 million and a 52-week range of $0.80 to $2.95. Moving from $1.66 to $7.60 represents about 358% upside — by any standard a very large move. The stock trades above its 200-day average (near $1.63) but below its 50-day average (near $1.89), reflecting a recent pullback within a longer-term recovery. Reaching $7.60 would almost certainly require positive proof-of-concept clinical data, likely for izicopan in AAV, rather than incremental news flow alone.
What Could Support a Move Toward the Target
Several verified factors could underpin upward movement. The company's pivot toward izicopan in AAV targets validated C5aR biology, with analysts citing potentially improved potency, reduced hepatotoxicity risk, and simpler dosing versus existing therapies. A $150 million financing announced earlier in 2026 extended the cash runway, reducing near-term capital risk. Multiple firms raised targets or upgraded ratings through 2026, signaling improving sentiment, and the pipeline also includes the hidradenitis suppurativa program, which the company has indicated could be partnered.
What Could Prevent the Target From Being Reached
The risks are substantial and concentrated. As a clinical-stage company, IFRX generates little recurring revenue, so the stock depends on trial outcomes that can fail or be delayed. Future development will likely require additional capital, which could dilute existing holders. Leerink Partners' Market Perform rating with a $2 target underscores a far more conservative view of the same assets. The stock's micro-cap size also leaves it exposed to volatility, and a broad rotation away from speculative biotech or weaker financing conditions could compress valuations regardless of company progress.
Technical Levels and Market Structure
The 52-week high near $2.95 is the nearest major overhead resistance, followed by psychological levels that emerge only after a decisive breakout. Support is anchored by the 200-day average near $1.63 and the 52-week low near $0.80. The stock's position between its 50-day and 200-day moving averages indicates the long-term uptrend has not fully reasserted itself, and any move toward $7.60 would first require clearing the prior high with meaningful volume.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may differ. The next earnings release is scheduled for early November 2026. Investors should watch for proof-of-concept data on izicopan in AAV, updates on the hidradenitis suppurativa partnering strategy, additional financing arrangements, and any further analyst revisions. Given the target's distance from the current price, clinical catalysts — not quarterly financials — will be the primary driver.
AI Daily Buy/Sell Signals
In my own work, Tickeron's AI Daily Buy/Sell Signals have become a useful part of the process for monitoring names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. For an event-driven stock such as IFRX, these signals help surface potential opportunities and track evolving setups without relying solely on manual chart review.
Final Assessment
Can IFRX reach $7.60? The target is a calculated average of eight analyst price targets spanning $2.00 to $14.00, implying roughly 358% upside from $1.66. Support rests on the izicopan AAV program, a strengthened cash position, and a cluster of bullish revisions in 2026. The obstacles are equally clear: clinical-stage risk, no recurring revenue, likely future dilution, and a wide analyst range that includes a $2 bearish outlier. The wide dispersion means the mean is not a reliable forecast for any individual path. What matters next is clinical data and financing, not the headline target itself.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IFRX's RSI Indicator climbs out of oversold territory
The RSI Indicator for IFRX moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 27 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for IFRX just turned positive on October 21, 2026. Looking at past instances where IFRX's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
Following a +2.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where IFRX advanced for three days, in 185 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
IFRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IFRX as a result. In 88 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
IFRX moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IFRX crossed bearishly below the 50-day moving average on September 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 20 of 23 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IFRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for IFRX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.673) is normal, around the industry mean (3.037). P/E Ratio (-3.320) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. IFRX's P/S Ratio (3333.333) is slightly higher than the industry average of (439.237).
The Tickeron Seasonality Score of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. IFRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IFRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceutical products
Industry Biotechnology